



The first total synthesis of a 12-membered macrolide balticolid

Palakodety Radha Krishna*, Sunchu Prabhakar, D. Venkata Ramana

D-211, Discovery Laboratory, Organic & Biomolecular Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India

ARTICLE INFO

Article history:

Received 22 August 2012

Revised 5 October 2012

Accepted 6 October 2012

Available online 13 October 2012

Keywords:

Balticolid

12-Membered macrolide

Anti-HSV activity

Ring-closing metathesis

ABSTRACT

Herein the first total synthesis of balticolid, a 12-membered macrolide is described.

© 2012 Elsevier Ltd. All rights reserved.

Many novel pharmacologically active secondary metabolites have been isolated from marine microorganisms.¹ Several 12-membered macrolides have been isolated from fungal metabolites (for e.g. cladospolides,² pandangolides³). Balticolid **1**, a new 12-membered macrolide was isolated by Shushni et al.,⁴ from the marine fungus belonging to the *Ascomycetous* species. The structure was determined as (4*R*,5*E*,9*E*,12*R*)-4-hydroxy-12-methyloxacyclododeca-5,9-diene-2,8-dione possessing an antiviral activity (*anti*-HSV) with an IC₅₀ value of 0.45 μM. Structurally, balticolid attracted our attention due to its differently positioned functional groups than related macrolides. For instance, the presence of a sensitive methylene at C7 flanked by the vinyl ketone (C8–C10) and allylic alcohol (C4–C6) moieties along with the two *E*-olefinic bonds at C5–C6 and C9–C10 makes this molecule synthetically interesting (Fig. 1). As a part of our interest in the synthesis of such biologically active macrolides,⁵ herein we describe the total synthesis of balticolid **1**.

Ever since the discovery of Grubbs catalyst, metathesis⁶ based synthetic strategies of natural products not only influenced the way synthetic chemists think but also shortened the sequences en route. Our synthetic plan (Scheme 1) involved RCM of the ester **5** that could be accessed from intermediates **6** and **7**, to furnish macrocycle **4a**. Alcohol **6** and acid **7** were synthesized independently. Subsequent transformations of macrocycle **4a** resulted in target compound **1**.

Thus, the synthesis of balticolid **1** primarily involved the synthesis of two key fragments **6** and **7** followed by their transformations into the target. Firstly, synthesis of alcohol intermediate **6**

was undertaken (Scheme 2). Accordingly, base induced ring-opening reaction of (*R*)-propylene oxide with protected propargyl alcohol resulted in the corresponding alkylated propargylic alcohol which on reported^{5a} transformations gave the allylic alcohol **8**. Compound **8** on oxidation (IBX/DMSO/EtOAc/rt/3 h) afforded the aldehyde (85%), which was further converted to **9** on Barbier allylation (Zn/allylbromide/satd. NH₄Cl/THF/0 °C to rt/12 h) followed by the protection of the ensuing alcohol as its silyl-ether (TBS-Cl/imidazole/DMAP/CH₂Cl₂/0 °C to rt/1 h). Furthermore compound **9** on PMB-deprotection (DDQ conditions⁷) furnished the requisite alcohol **6** (80%).

Next, the synthesis of the acid component **7** (Scheme 3) was taken up. Accordingly, allylic alcohol **10** was identified as an important precursor and hence synthesis of **10** was accomplished by adopting a literature inspired procedure.^{5c} Further, compound **10** was converted into its MOM-ether (MOM-Cl/DIPEA/CH₂Cl₂/0 °C to rt/12 h) to afford compound **11** (90%). The silyl group in compound **11** was deprotected under conventional conditions (TBAF/THF/0 °C to rt/2 h) to afford the corresponding primary alcohol that was oxidized^{8a} {TEMPO/BIAB/CH₂Cl₂:H₂O (1:1)/0 °C to rt/2 h} to the desired acid **7** (91% over two steps).^{8b}





Figure 1.


* Corresponding author. Fax: +91 40 27160387.

E-mail address: prkgenius@iict.res.in (P. Radha Krishna).



Scheme 1. Retrosynthesis.

Synthesis of alcohol fragment 6




Scheme 2. Reagents and conditions: (a) (i) IBX, DMSO, EtOAc, rt, 3 h, 85%; (ii) Zn, allylbromide, THF, satd. NH_4Cl , 0 °C to rt, 12 h, 85%; (iii) TBS-Cl, imidazole, cat. DMAP, CH_2Cl_2 , 0 °C to rt, 1 h, 95%, (b) DDQ, $\text{CH}_2\text{Cl}_2:\text{H}_2\text{O}$ (18:1), 0 °C to rt, 1 h, 80%.



Having the requisite fragments **6** and **7** in hand, esterification (DCC/DMAP/ CH_2Cl_2 /0 °C to rt, Scheme 4) between them furnished ester **5** (79%). Next, the crucial RCM of ester **5** (G-II/ CH_2Cl_2 /reflux/12 h) resulted in chromatographically inseparable diastereomeric macrolides **4** (1:1 ratio in 75% combined yield), epimeric at C8

center as a single geometric isomer. However, no efforts were made to separate the isomers because the epimeric carbon eventually transforms into a ketone functionality in further steps. Thus, the epimeric mixture of macrolides **4** on desilylation (TBAF/THF/0 °C to rt/2 h) followed by oxidation (Dess–Martin periodinane/ CH_2Cl_2 /0 °C to rt/2 h) gave macrocyclic vinyl ketone **12** (82%), which on further deprotection (PMB-silica/neat/rt/0.5 h) of MOM-group gave the presumable target macrolide in 95% yield as an exclusive geometric isomer. This compound was characterized from its spectral data.⁹ The spectral data of the synthetic sample did not match with the reported one. For instance, its ^1H NMR spectrum revealed the characteristic allylic olefinic proton (H4) appearing at δ 4.35–4.27 ppm as a multiplet and H5 proton and H6 appearing at δ 5.53–5.47 as a multiplet, while the same proton (H4) reportedly resonated at δ 4.54 ppm as a multiplet and H5 proton at δ 5.73 as a dd ($J = 15.9, 2.8$ Hz) and H6 at δ 5.75 as a multiplet. The ^{13}C NMR spectrum too revealed certain discrepancies: for instance C4 appeared at

Synthesis of acid fragment 7



Scheme 3. Reagents and conditions: (a) MOM-Cl, DIPEA, CH_2Cl_2 , 0 °C to rt, 12 h, 90%, (b) (i) TBAF, THF, 0 °C to rt, 2 h, 91%; (ii) TEMPO, BAIB, $\text{CH}_2\text{Cl}_2:\text{H}_2\text{O}$ (1:1), 0 °C to rt, 2 h, 91%.



Scheme 4. Reagents and conditions: (a) DCC, DMAP, CH_2Cl_2 , 0 °C to rt, 12 h, 79%, (b) G-II (10 mol %), CH_2Cl_2 , reflux, 12 h; 75%, (c) (i) TBAF, THF, 0 °C to rt, 2 h, 80%; (ii) Dess–Martin periodinane, CH_2Cl_2 , 0 °C to rt, 2 h, 82%, (d) PMB-silica, neat, 0.5 h, 95%, (e) HG-II (10 mol %), toluene, reflux, 12 h, 70%, (f) (i) TBAF, THF, 0 °C to rt, 2 h, 82%; (ii) Dess–Martin periodinane, CH_2Cl_2 , 0 °C to rt, 2 h, 83%, (g) PMB-silica, neat, 0.5 h, 93%.

δ 71.5 ppm in contrast to the reported value at δ 69.1 ppm while C6 appeared at δ 128.6 ppm instead of at δ 125.2 ppm. Also, the specific rotation value did not match with the reported value $\{[\alpha]_D^{25} +195.2$ (c 0.25, MeOH); Lit.⁴ $[\alpha]_D^{25} +135.2$ (c 0.35, MeOH)}. Based on the above data, the geometry of the newly formed double bond was tentatively assigned as *Z* and the compound was christened as **Z-1**.⁹

Hence, ester **5** on RCM under Hoveyda-Grubbs II conditions (Scheme 4, conditions e¹⁰) gave a mixture of separable macrolides **4** and **4a** (1:3 ratio, 70% combined yield) as respective epimers. Each macrolide set was separated and characterized independently.⁹ The less polar minor macrolide set was found to have comparable data with the macrolide-**4** that was obtained earlier under G-II conditions and matched when a co-tlc was run. Since macrolide **4** was already shown to afford isomeric target molecule (**Z-1**), it was decided that the rest of the synthetic sequence be carried out on macrolide **4a**. Thus, compound **4a**, which was thought to be different due to its *E*-geometry around the newly formed double bond, was taken up next. Accordingly, epimeric mixture of macrolide **4a** on desilylation (TBAF/THF/0 °C to rt/2 h) followed by oxidation (Dess–Martin periodinane/CH₂Cl₂/0 °C to rt/2 h) furnished macrocyclic vinyl ketone **12a** (83%), which on further deprotection of MOM-group, under similar conditions as mentioned above, gave balticolid **1** (93%). Compound **1** was characterized by its spectral data. The spectral data of the synthetic sample matched with the reported data and hence assigned as **1**.^{4,9} For instance, the ¹H NMR spectrum of **1** revealed the characteristic allylic olefinic proton (C4) at δ 4.50 ppm as a broad singlet and C5 proton and C6 appearing at δ 5.74–5.65 as a multiplet. The ¹³C NMR spectrum of **1** displayed C4 at δ 69.0 ppm while C6 appeared at δ 125.1 ppm. The specific rotation was found to be $[\alpha]_D^{25} +141.2$ (c 0.38, MeOH) [Lit.⁴ $[\alpha]_D^{25} +135.2$ (c 0.35, MeOH)]. HRMS spectrum of **1** displayed the $[M+Na]^+$ at 247.0934 while calculated gave 247.0940 for the molecular formula C₂₁H₂₆O₃Na as an additional support.

In summary, synthesis of balticolid **1** was accomplished via Hoveyda-Grubbs II catalyst assisted RCM of ester **5** in good yields and selectivity. The key intermediates **6** and **7** were accessed from common and inexpensive starting materials. Alongside, isomeric balticolid **Z-1** was also synthesized.

Acknowledgments

Two of the authors (S.P. and D.V.R.) thank the CSIR, New Delhi for the financial support in the form of fellowships.

References and notes

- (a) Liberra, K.; Lindequist, U. *Pharmazie* **1995**, *50*, 583–588; (b) Blunt, J. W.; Copp, B. R.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2011**, *28*, 196–268.
- Hirota, A.; Sakai, H.; Isogai, A. *Agric. Biol. Chem.* **1985**, *49*, 731–735.
- Jadulco, R.; Proksch, P.; Wray, V.; Sudarsono; Berg, A.; Grafe, U. *J. Nat. Prod.* **2001**, *64*, 527–530.
- Shushni, M. A. M.; Singh, R.; Mentel, R.; Lindequist, U. *Mar. Drugs* **2011**, *9*, 844–851.
- (a) Radha Krishna, P.; Ramana, D. V.; Reddy, B. K. *Synlett* **2009**, 2924–2926; (b) Radha Krishna, P.; Jagannadha Rao, T. *Org. Biomol. Chem.* **2010**, *8*, 3130–3132; (c) Radha Krishna, P.; Jagannadha Rao, T. *Tetrahedron Lett.* **2010**, *51*, 4017–4019; (d) Radha Krishna, P.; Anitha, K. *Tetrahedron Lett.* **2011**, *52*, 4546–4549.
- (a) Chatterjee, A. K.; Grubbs, R. H. *Angew. Chem., Int. Ed.* **2002**, *41*, 3171–3174; (b) Hoveyda, A. H.; Zhugralin, A. R. *Nature* **2007**, *250*, 243–251; (c) Vougioukalakis, G. C.; Grubbs, R. H. *Chem. Rev.* **2010**, *110*, 1746–1787.
- Horita, K.; Yoshioka, T.; Tanaka, T.; Oikawa, Y.; Yonemitsu, O. *Tetrahedron* **1986**, *42*, 3021–3028.
- (a) Epp, J. B.; Widlanski, T. S. *J. Org. Chem.* **1999**, *64*, 293–295; (b) Phaneendra Reddy, B.; Pandurangam, T.; Yadav, J. S.; Subba Reddy, B. V. *Tetrahedron Lett.* **2012**, *53*, 5749–5752.
- Spectral data of some selected compounds. Compound 11*: Pale yellow liquid. $[\alpha]_D^{25} +141.1$ (c 0.75, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 5.71–5.64 (m, 1H), 5.22–5.10 (m, 2H), 4.66 (d, 1H, *J* = 7.0 Hz), 4.50 (d, 1H, *J* = 6.5 Hz), 4.14 (q, 1H, *J* = 7.0 Hz), 3.73–3.63 (m, 2H), 3.34 (br s, 3H), 1.84–1.76 (m, 1H), 1.70–1.64 (m, 1H), 0.89 (br s, 9H), 0.04 (br s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 138.2, 117.0, 93.8, 74.2, 59.2, 55.3, 38.2, 25.8, –5.3; HRMS: *m/z* calcd for C₁₃H₂₆O₃NaSi $[M+Na]^+$: 283.1699; found: 283.1704. *Compound 7*: Pale yellow liquid. $[\alpha]_D^{25} +193.4$ (c 0.25, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 5.77–5.63 (m, 1H), 5.34–5.22 (m, 2H), 4.65 (d, 1H, *J* = 6.7 Hz), 4.54–4.44 (m, 2H), 3.33 (br s, 3H), 2.70–2.44 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ 176.3, 136.3, 118.3, 93.9, 73.5, 55.5, 40.7; HRMS: *m/z* calcd for C₇H₁₂O₄Na $[M+Na]^+$: 183.0627; found: 183.0631. *Compound 9*: Colorless liquid. $[\alpha]_D^{25} -11.76$ (c 0.35, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 7.18 (d, 2H, *J* = 8.3 Hz), 6.79 (d, 2H, *J* = 8.3 Hz), 5.80–5.60 (m, 1H), 5.59–5.40 (m, 2H), 5.02–4.96 (m, 2H), 4.40 (dd, 2H, *J* = 18.8, 11.3 Hz), 4.06 (q, 1H, *J* = 12.0, 6.0 Hz), 3.78 (br s, 3H), 3.54–3.46 (m, 1H), 2.38–2.09 (m, 4H), 1.13 (d, 3H, *J* = 6.0 Hz), 0.87 (br s, 9H), 0.02 (d, 6H, *J* = 7.5 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 158.9, 135.3, 135.1, 130.9, 129.0, 126.3, 116.5, 113.6, 74.3, 73.2, 69.9, 55.1, 43.0, 39.1, 39.0, 25.8, 19.4, 18.2, –4.7, –4.2; HRMS: *m/z* calcd for C₂₃H₃₈O₃NaSi $[M+Na]^+$: 413.2482; found: 413.2491. *Compound 6*: Yellow oil. $[\alpha]_D^{25} -3.07$ (c 0.15, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 5.82–5.68 (m, 1H), 5.59–5.46 (m, 2H), 5.01 (br d, *J* = 15.5 Hz), 4.16–4.09 (m, 1H), 3.80–3.73 (m, 1H), 2.29–2.16 (m, 3H), 2.16–2.05 (m, 1H), 1.17 (d, 3H, *J* = 6.0 Hz), 0.89 (s, 9H), 0.03 (d, 6H, *J* = 11.0 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 136.7, 134.9, 125.9, 116.8, 72.7, 66.9, 43.0, 41.9, 25.7, 22.5, 18.1, –4.8; HRMS: *m/z* calcd for C₁₅H₃₀O₂NaSi $[M+Na]^+$: 293.1907; found: 293.1910. *Compound 5*: Yellow oil. $[\alpha]_D^{25} +138.2$ (c 0.35, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 5.76–5.64 (m, 2H), 5.48–5.45 (m, 2H), 5.30 (d, 1H, *J* = 17.1 Hz), 5.19 (d, 1H, *J* = 9.9 Hz), 5.01–4.98 (m, 2H), 4.92–4.86 (m, 1H), 4.63 (d, 1H, *J* = 6.6 Hz), 4.50 (d, 1H, *J* = 6.6 Hz), 4.43 (m, 1H), 4.08–4.07 (m, 1H), 3.80 (br s, 3H), 2.60–2.54 (m, 1H), 2.42–2.38 (m, 1H), 2.31–2.16 (m, 3H), 1.19 (d, 3H, *J* = 6.0 Hz), 0.87 (br s, 9H), 0.01 (d, 6H, *J* = 12.1 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 170.1, 136.8, 134.9, 124.7, 117.9, 116.7, 94.1, 73.9, 72.9, 70.6, 60.3, 55.5, 43.0, 41.1, 38.4, 29.6, 25.8, 20.9, 19.3, 18.2, 14.1, –4.7; HRMS: *m/z* calcd for C₂₂H₄₀O₅NaSi $[M+Na]^+$: 435.2548; found: 435.2675. *Compound 4*: Pale yellow liquid. $[\alpha]_D^{25} +202.5$ (c 0.35, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 5.44–5.36 (m, 1H), 5.21–5.12 (m, 4H), 4.69 (d, 1H, *J* = 6.4 Hz), 4.52 (d, 1H, *J* = 6.4 Hz), 4.36–4.29 (m, 1H), 4.01–3.94 (m, 1H), 3.35 (s, 3H), 2.72 (dd, 1H, *J* = 12.8, 3.9 Hz), 2.48–2.38 (m, 2H), 1.23 (d, 3H, *J* = 6.4 Hz), 0.86 (s, 9H), 0.02 (d, 6H, *J* = 10.3 Hz); ¹³C NMR (300 MHz, CDCl₃): δ 169.8, 135.8, 122.0, 128.1, 93.4, 74.6, 73.9, 68.6, 55.4, 42.0, 40.7, 25.8, 20.7, –4.3; HRMS: *m/z* calcd for C₂₀H₃₆O₅NaSi $[M+Na]^+$: 407.2224; found: 407.2231. *Compound 4a*: Yellow oil. $[\alpha]_D^{25} +171.9$ (c 0.17, CHCl₃); ¹H NMR (75 MHz, CDCl₃): δ 5.67–5.53 (m, 1H), 5.39–5.12 (m, 3H), 5.09–5.00 (m, 1H), 4.69 (br s, 2H), 4.44–4.36 (m, 1H), 4.19–4.10 (m, 1H), 3.41 (s, 3H), 2.75–2.63 (m, 1H), 2.56 (dd, 1H, *J* = 13.7, 3.5 Hz), 2.48–2.30 (m, 2H), 2.24–2.05 (m, 2H), 1.24 (d, 3H, *J* = 7.9 Hz), 0.89 (s, 9H), 0.04 (d, 6H, *J* = 5.4 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 169.4, 143.0, 136.0, 131.1, 128.3, 126.4, 94.3, 72.8, 71.9, 69.4, 55.4, 41.1, 40.4, 39.1, 25.8, 20.2, 18.2, –4.5; HRMS: *m/z* calcd for C₂₀H₃₆O₅NaSi $[M+Na]^+$: 407.2224; found: 407.2221. *Compound 12*: Yellow oil. $[\alpha]_D^{25} +130.6$ (c 0.15, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 6.59–6.53 (m, 1H), 5.94 (d, 1H, *J* = 16.1 Hz), 5.72–5.66 (m, 1H), 5.45–5.34 (m, 1H), 5.24–5.17 (m, 1H), 4.66 (d, 1H, *J* = 6.4 Hz), 4.52 (d, 1H, *J* = 6.8 Hz), 4.41–4.36 (m, 1H), 3.38–3.30 (m, 4H), 3.18 (dd, 1H, *J* = 13.7, 4.0 Hz), 2.82 (dd, 1H, *J* = 12.5, 4.0 Hz), 2.47 (br t, 1H, *J* = 12.1 Hz), 2.39–2.28 (m, 2H), 1.30 (d, 3H, *J* = 6.0 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 198.8, 169.3, 144.6, 134.0, 131.9, 129.9, 93.7, 74.4, 69.6, 55.3, 45.1, 41.9, 38.7, 20.8; HRMS: *m/z* calcd for C₁₄H₂₀O₅Na $[M+Na]^+$: 291.1208; found: 291.1202. *Compound 12a*: Pale yellow oil. $[\alpha]_D^{25} +110.4$ (c 0.25, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 6.67–6.56 (m, 1H), 5.91 (d, 1H, *J* = 16.2 Hz), 5.87–5.77 (m, 1H), 5.48 (dd, 1H, *J* = 15.8, 4.9 Hz), 5.14–5.03 (m, 1H), 4.68 (dd, 2H, *J* = 14.5, 6.9 Hz), 4.47–4.45 (m, 1H), 3.40 (br s, 3H), 3.26 (d, 2H, *J* = 6.6 Hz), 2.76 (dd, 1H, *J* = 13.4, 4.5 Hz), 2.52 (dd, 1H, *J* = 13.4, 3.9 Hz), 2.49–2.28 (m, 1H), 1.30 (d, 3H, *J* = 6.2 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 197.3, 169.1, 144.9, 134.0, 131.9, 126.0, 122.1, 94.5, 71.8, 55.5, 51.9, 50.8, 50.6, 40.8, 38.4, 20.5; HRMS: *m/z* calcd for C₁₄H₂₀O₅Na $[M+Na]^+$: 291.1208; found: 291.1199. *Balticolid Z-1*: Yellow oil. $[\alpha]_D^{25} +195.0$ (c 0.25, MeOH); ¹H NMR (75 MHz, CD₃OD): δ 6.60 (m, 1H), 5.87 (d, 1H, *J* = 16.2 Hz), 5.53–5.47 (m, 2H), 5.09 (m, 1H), 4.28 (m, 1H), 3.36–3.29 (m, 1H), 3.0 (dd, 1H, *J* = 14.3, 3.3 Hz), 2.63 (dd, 1H, *J* = 12.4, 4.7 Hz), 2.40–2.17 (m, 3H), 1.21 (d, 3H, *J* = 6.2 Hz); ¹³C NMR (75 MHz, CD₃OD): δ 202.0, 171.8, 147.5, 138.1, 132.8, 128.6, 72.1, 71.5, 45.9, 44.8, 39.7, 21.1; HRMS: *m/z* calcd for C₁₂H₁₆O₄Na $[M+Na]^+$: 247.0940; found: 247.0948. *Balticolid 1*: Pale yellow oil. $[\alpha]_D^{25} +142.5$ (c 0.38, MeOH); ¹H NMR (500 MHz, CD₃OD): δ 6.76–6.68 (m, 1H), 5.95 (d, 1H, *J* = 16.3 Hz), 5.74–5.64 (m, 2H), 5.11–5.03 (m, 1H), 4.50–4.49 (m, 1H), 3.37 (dd, 1H, *J* = 13.2, 6.6 Hz), 3.19–3.15 (m, 1H), 2.63 (dd, 1H, *J* = 13.5, 4.6 Hz), 2.58 (dd, 1H, *J* = 13.2, 3.4 Hz), 2.50–2.45 (m, 1H), 2.36–2.28 (m, 1H), 1.28 (d, 3H, *J* = 6.2 Hz); ¹³C NMR (75 MHz, CD₃OD): δ 202.5, 171.8, 148.0, 138.2, 132.6, 125.0, 72.0, 69.0, 45.6, 43.2, 39.5, 21.0; HRMS: *m/z* calcd for C₁₂H₁₆O₄Na $[M+Na]^+$: 247.0940; found: 247.0934.
- The authors are thankful to the referees for asking us to describe all the RCM reactions performed. The set of RCM reactions used are as follows: firstly the RCM of compound **5** was conducted in reflux methylene chloride under G-II catalyst which resulted in macrocycle as an exclusive *Z*-isomer with complete consumption of starting material. Next, in order to check if temperature plays a role in altering the double bond geometry, the same reaction was conducted in reflux toluene. Yet, the macrocycle obtained was again *Z*-isomer. Hence, when the RCM was performed with Hoveyda-Grubbs II catalyst in reflux methylene chloride, two macrocyclic products (*Z*:*E* = 1:1 based on tlc) were formed though no complete conversion of the started material **5** was observed. However, for the same reaction when conducted at elevated temperature in toluene, complete conversion was observed to result in macrocyclic products with altered geometric ratio in favor of *E*-isomer (*Z*:*E* = 1:3 based on tlc). It may be deduced that while the conversion (RCM under HG-II conditions) was dependent on temperature, the double bond geometry was dependent both on the catalyst and the temperature.